When Ajay Piramal acquired Nicholas Laboratories India in 1988, he was a textile manufacturer making an unlikely pivot into healthcare. Nearly four decades later, that bet has produced a $1.07 billion pharmaceutical company with 17 global facilities across three continents, 11 FDA-registered plants, and the Carlyle Group as a 20% strategic investor. Piramal Pharma has become one of India’s leading contract development and manufacturing organisations, serving the world’s largest pharmaceutical companies from facilities in North America, Europe, and India.
Ajay Piramal’s entry into healthcare was not a natural progression. The Piramal family had built its business in textiles, and in 1988, when Piramal acquired Nicholas Laboratories India, a subsidiary of the Australian pharmaceutical company Nicholas Kiwi, the move was viewed as an unexpected diversification. But Piramal saw what many of his contemporaries in Indian business did not: that pharmaceutical manufacturing would become one of India’s most significant export industries, and that the companies positioned early would capture disproportionate value.
The Nicholas acquisition gave Piramal a foothold in pharmaceutical manufacturing, regulatory know-how, and a product portfolio to build upon. Over the following decades, the company expanded through a combination of organic growth and targeted acquisitions, gradually shifting its centre of gravity from domestic branded pharmaceuticals toward contract development and manufacturing for global pharmaceutical companies.
That strategic evolution culminated in the company’s demerger from Piramal Enterprises and separate listing on the BSE and NSE in August 2022, giving Piramal Pharma its own public-market identity and capital structure for the first time.
Piramal Pharma Solutions, the company’s contract development and manufacturing organisation, is the largest division by revenue, contributing INR 5,447 crore in FY25. The CDMO operates 17 facilities across three continents: four in North America, two in Europe, and nine or more in India. Eleven of these facilities carry US FDA registration, and the company has received 29 FDA drug approvals, reflecting the regulatory standard required to serve major pharmaceutical clients.
The geographic spread of these facilities is not accidental. Large pharmaceutical companies increasingly require their contract manufacturers to maintain production capacity close to end markets, both for supply-chain resilience and to satisfy regulatory expectations around manufacturing proximity. By operating in North America, Europe, and India, Piramal can offer clients multi-site manufacturing strategies that reduce concentration risk and provide flexibility across product lifecycles.
Headquartered in Mumbai, the company employs approximately 6,700 people across its global operations, with capabilities spanning active pharmaceutical ingredient synthesis, finished dosage formulation, sterile injectables, and high-potency active ingredients.
While the CDMO business defines Piramal Pharma’s identity in global pharmaceutical circles, the company operates three additional divisions that diversify its revenue base and provide exposure to different segments of the healthcare value chain.
Piramal Critical Care manufactures and markets hospital-use products, including inhalation anaesthetics, injectable analgesics, and intrathecal therapies, serving healthcare systems primarily in North America and Europe. The India Consumer Healthcare division operates in the domestic over-the-counter market. And through a joint venture with AbbVie, the company participates in branded therapeutics distribution in India.
This four-division structure means Piramal Pharma is not solely dependent on the contract manufacturing cycle, where revenue can fluctuate with client pipeline timelines and procurement decisions. The Critical Care and Consumer Healthcare businesses provide more predictable revenue streams, while the AbbVie joint venture offers exposure to innovative therapies without the full cost and risk of proprietary drug development.
In October 2020, the Carlyle Group made a 20% strategic investment in Piramal Pharma, a significant endorsement from one of the world’s largest private equity firms. Carlyle’s investment thesis centred on the structural growth in pharmaceutical outsourcing, the quality of Piramal’s manufacturing network, and the potential for operational improvements across the company’s global facilities.
Two years later, in August 2022, Piramal Pharma was demerged from Piramal Enterprises and listed separately on both the BSE and NSE. The demerger gave the pharmaceutical business its own balance sheet, management focus, and public-market valuation, allowing investors to evaluate the CDMO, Critical Care, and Consumer Healthcare operations on their own merits rather than as a division within a conglomerate.
By FY25, the company had crossed $1 billion in annual revenue, reaching INR 9,151 crore. The Carlyle investment and the separate listing together represent a maturation point: the transition from a family-business division to a standalone, institutionally backed pharmaceutical company competing on the global stage.
Sources: Piramal Pharma Limited Annual Report FY2024–25. Piramal Pharma Investor Presentations. BSE/NSE filing disclosures. US FDA facility registration data. Carlyle Group press releases.